CP
SLNO

Clayton Partners’s Soleno Therapeutics SLNO Stock Holding History

Clayton Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,000
Closed -$207K – 36
2023
Q3 		$207K Buy
+7,000
New +$42.4K 0.18% 36
2023
Q2 		– Sell
-92,772
Closed -$199K – 37
2023
Q1 		$199K Hold
92,772
– – 0.19% 30
2022
Q4 		$184K Sell
92,772
-7,228
-7% -$8.99K 0.17% 30
2022
Q3 		$167K Buy
+100,000
New +$243K 0.19% 30
2021
Q2 		– Sell
-6,667
Closed -$126K – 40
2021
Q1 		$126K Buy
+6,667
New +$215K 0.12% 33

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Clayton Partners's SLNO Position: Q4 2023 in Review

Clayton Partners sold out of Soleno Therapeutics (SLNO) in Q4 2023, closing a stake of 7,000 shares — an estimated $207K sold.

Clayton Partners first reported a position in SLNO in Q1 2021 and held it in 5 quarters. The position peaked at $207K in Q3 2023. 76 funds tracked by Wall St. Rank hold SLNO as of Q4 2023.

  • Clayton Partners reported no remaining Soleno Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Clayton Partners sold 7,000 Soleno Therapeutics shares in Q4 2023, an estimated $207K.
  • Clayton Partners first reported a position in Soleno Therapeutics in Q1 2021 and held it in 5 quarters.
  • Clayton Partners's Soleno Therapeutics position peaked at $207K in Q3 2023.
  • 76 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2023.

Based on Clayton Partners's 13F filing for Q4 2023, filed 14 Feb 2024.